Prostate cancer: an evolving paradigm.


Journal Article

Since at least the early 1990s, stage and risk migration have been seen in patients with prostate cancer, likely corresponding to the institution of prostate specific antigen (PSA) screening in health systems. Preoperative risk factors, including PSA level and clinical stage, have decreased significantly. These improved prognostic variables have led to a larger portion of men being stratified with low-risk disease, as per the classification of D'Amico and associates. This, in turn, has corresponded with more favorable postoperative variables, including decreased extraprostatic tumor extension and prolonged biochemical-free recurrence rates. The advent of focal therapy is bolstered by findings of increased unilateral disease with decreased tumor volume. Increasingly, targeted or delayed therapies may be possible within the current era of lower risk disease.

Full Text

Duke Authors

Cited Authors

  • Caso, JR; Mouraviev, V; Tsivian, M; Polascik, TJ; Moul, JW

Published Date

  • May 2010

Published In

Volume / Issue

  • 24 / 5

Start / End Page

  • 805 - 809

PubMed ID

  • 20367442

Pubmed Central ID

  • 20367442

Electronic International Standard Serial Number (EISSN)

  • 1557-900X

Digital Object Identifier (DOI)

  • 10.1089/end.2009.0539


  • eng

Conference Location

  • United States